Drug Trial Radar · NCT07227246
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
May 6, 2025
Primary completion
Jan 2029
Study completion Jun 2029
Sponsor
- Lead sponsor
- Joseph Broderick, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS); Japan Agency for Medical Research and Development; Novo Nordisk A/S
- First posted
- Nov 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 90 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include those treated within 2 hours with a positive spot sign on a baseline CT angiogram or patients treated within 90 minutes of stroke onset, with or without a positive spot sign.
Conditions
- Intracerebral Hemorrhage
Interventions
Recombinant Factor VIIaBiological
Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. All participants in FASTEST Part 2 must have a positive spot sign on baseline CTA and be treated within 120 minutes of onset or patients treated within 90 minutes of stroke onset, with or without a positive spot sign. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
Biological/Vaccine: PlaceboBiological
Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. All participants in FASTEST Part 2 must have a positive spot sign on baseline CTA and be treated within 120 minutes of onset or patients treated within 90 minutes of stroke onset, with or without a positive spot sign. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Modified Rankin ScaleTime frame: 90 days
Locations
88 sites in 6 countries. Site status is shown where the registry gives one.
University of Alabama Hospital
Birmingham, Alabama · Recruiting
Kaiser Permanente Baldwin Park Medical Center
Baldwin Park, California · Recruiting
Mills Peninsula Medical Center
Burlingame, California · Recruiting
Kaiser Permanente Downey Medical Center
Downey, California · Recruiting
Kaiser Permanente Fontana Medical Center
Fontana, California · Recruiting
Kaiser Permanente South Bay Medical Center
Harbor City, California · Recruiting
UCSD Health La Jolla
La Jolla, California · Recruiting
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California · Recruiting
Kaiser Permanente West Los Angeles Medical Center
Los Angeles, California · Recruiting
Ronald Reagan UCLA Medical Center
Los Angeles, California · Recruiting
UC Irvine Medical Center,
Orange, California · Recruiting
Kaiser Permanente Riverside Medical Center
Riverside, California · Recruiting
UC Davis Medical Center
Sacramento, California · Recruiting
UCSD Medical Center - Hillcrest Hospital
San Diego, California · Recruiting
San Francisco General Hospital
San Francisco, California · Recruiting
UF Health Shands Hospital
Gainesville, Florida · Recruiting
University of Florida Jacksonville (UF Health)
Jacksonville, Florida · Recruiting
Mayo Clinic
Jacksonville, Florida · Recruiting
Grady Memorial Hospital
Atlanta, Georgia · Recruiting
WellStar Kennestone Hospital
Marietta, Georgia · Recruiting
The Queen's Medical Center
Honolulu, Hawaii · Recruiting
Northwestern Memorial Hospital
Chicago, Illinois · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
Central DuPage Hospital
Winfield, Illinois · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
UMass Memorial Medical Center
Worcester, Massachusetts · Recruiting
Henry Ford Hospital
Detroit, Michigan · Recruiting
M Health Fairview Ridges Hospital,
Burnsville, Minnesota · Recruiting
M Health Fairview Southdale Hospital
Edina, Minnesota · Recruiting
M Health Fairview St. John's Hospital
Maplewood, Minnesota · Recruiting
M Health Fairview University of Minnesota Medical Center Hospital,
Minneapolis, Minnesota · Recruiting
Mayo Clinic Saint Marys Campus
Rochester, Minnesota · Recruiting
Barnes Jewish Hospital
St Louis, Missouri · Recruiting
Mount Sinai West
New York, New York · Recruiting
The Mount Sinai Hospital
New York, New York · Recruiting
Stony Brook University Hospital
Stony Brook, New York · Recruiting
University of Cincinnati Medical Center
Cincinnati, Ohio · Recruiting
OSU Wexner Medical Center
Columbus, Ohio · Recruiting
Riverside Methodist Hospital
Columbus, Ohio · Recruiting
St. John Medical Center
Tulsa, Oklahoma · Recruiting
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.